Evidence map›Paper›PMID 39880359›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2025

Shrinking the lymphatic filariasis map of Zimbabwe: Reassessing the population requiring treatment through confirmatory mapping.

Nicholas Midzi, Masceline Jenipher Mutsaka-Makuvaza, Isaac Phiri, Karen Palatio, Didier Bakajika, Honorat M Zouré, Elizabeth Juma, Molly Anderson, Rebecca Mwabvu, Moses J Bockarie and 2 more

Abstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nicholas MidziNational Institute of Health Research, Ministry of Health and Child Care, Harare, Zimbabwe. Electronic address: nmidzi@mohcc.org.zw.
Masceline Jenipher Mutsaka-MakuvazaNational Institute of Health Research, Ministry of Health and Child Care, Harare, Zimbabwe; Department of Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, Butare, Rwanda.
Isaac PhiriNational Institute of Health Research, Ministry of Health and Child Care, Harare, Zimbabwe.
Karen PalatioEND Fund, New York, NY, USA.
Didier BakajikaExpanded Special Project for Elimination of NTDs, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.
Honorat M ZouréExpanded Special Project for Elimination of NTDs, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.
Elizabeth JumaExpanded Special Project for Elimination of NTDs, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.
Molly AndersonEND Fund, New York, NY, USA.
Rebecca MwabvuHigherlife Foundation, Harare, Zimbabwe.
Moses J BockarieCollege of Medical Sciences, Njala University, Bo Campus, Freetown, Sierra Leone.
Jorge CanoExpanded Special Project for Elimination of NTDs, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.
Sammy M NjengaKenya Medical Research Institute, Nairobi, Kenya.

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectivesZimbabwe is endemic for lymphatic filariasis (LF) with 39 districts identified for mass drug administration (MDA) in 2014. The objective of this study was to reassess the current population requiring MDA.

methodsThe LF confirmatory mapping method was used to evaluate the prevalence of circulating filarial antigens among school-aged children (9-14 years) in previously endemic districts. This was achieved through a cross-sectional survey between 2021 and 2023, applying a cluster sampling approach across 39 districts, targeting 18,720 children to assess ongoing LF transmission.

resultsThe findings revealed a significant decline in LF prevalence, with an overall rate of 0.43%. Importantly, 82.05% of districts previously identified as endemic were reclassified as nonendemic. Only seven districts retained endemic status, necessitating continued MDA using the triple-drug therapy regimen. Population estimates based on 2022 census data indicated that 1.19 million individuals across these districts require MDA, representing an 84.4% reduction compared to previous estimates. Despite the progress, the persistence of low-level transmission in certain districts highlights the need for sustained surveillance and morbidity management services, including hydrocele surgery and lymphedema care.

conclusionThere was a significant reduction in the number of people requiring MDA. The decline in LF endemicity is attributed to a combination of factors, including prior rounds of MDA and vector control initiatives including historical interventions, such as dichlorodiphenyltrichloroethane spraying against human African trypanosomiasis.

Indexed as

Elephantiasis, FilarialFilaricidesAdolescentAnimalsAntigens, HelminthChildCross-Sectional StudiesEndemic DiseasesFemaleHumansMaleMass Drug AdministrationPrevalenceWuchereria bancroftiZimbabweAntigens, HelminthFilaricidesConfirmatory mappingLymphatic filariasisMass drug administrationNeglected tropical diseasesTripple therapy

Identifiers

PMID39880359
PMCPMC11873682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.